GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jiangsu Recbio Technology Co Ltd (HKSE:02179) » Definitions » Current Ratio

Jiangsu Recbio Technology Co (HKSE:02179) Current Ratio : 1.17 (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Jiangsu Recbio Technology Co Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Jiangsu Recbio Technology Co's current ratio for the quarter that ended in Jun. 2024 was 1.17.

Jiangsu Recbio Technology Co has a current ratio of 1.17. It generally indicates good short-term financial strength.

The historical rank and industry rank for Jiangsu Recbio Technology Co's Current Ratio or its related term are showing as below:

HKSE:02179' s Current Ratio Range Over the Past 10 Years
Min: 1.17   Med: 5.52   Max: 17.45
Current: 1.17

During the past 5 years, Jiangsu Recbio Technology Co's highest Current Ratio was 17.45. The lowest was 1.17. And the median was 5.52.

HKSE:02179's Current Ratio is ranked worse than
79.57% of 1503 companies
in the Biotechnology industry
Industry Median: 3.69 vs HKSE:02179: 1.17

Jiangsu Recbio Technology Co Current Ratio Historical Data

The historical data trend for Jiangsu Recbio Technology Co's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jiangsu Recbio Technology Co Current Ratio Chart

Jiangsu Recbio Technology Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Current Ratio
17.45 12.34 9.29 4.32 2.54

Jiangsu Recbio Technology Co Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Current Ratio Get a 7-Day Free Trial Premium Member Only 6.72 4.32 3.99 2.54 1.17

Competitive Comparison of Jiangsu Recbio Technology Co's Current Ratio

For the Biotechnology subindustry, Jiangsu Recbio Technology Co's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jiangsu Recbio Technology Co's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jiangsu Recbio Technology Co's Current Ratio distribution charts can be found below:

* The bar in red indicates where Jiangsu Recbio Technology Co's Current Ratio falls into.



Jiangsu Recbio Technology Co Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Jiangsu Recbio Technology Co's Current Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Current Ratio (A: Dec. 2023 )=Total Current Assets (A: Dec. 2023 )/Total Current Liabilities (A: Dec. 2023 )
=1235.284/485.895
=2.54

Jiangsu Recbio Technology Co's Current Ratio for the quarter that ended in Jun. 2024 is calculated as

Current Ratio (Q: Jun. 2024 )=Total Current Assets (Q: Jun. 2024 )/Total Current Liabilities (Q: Jun. 2024 )
=856.239/733.818
=1.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Jiangsu Recbio Technology Co  (HKSE:02179) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Jiangsu Recbio Technology Co Current Ratio Related Terms

Thank you for viewing the detailed overview of Jiangsu Recbio Technology Co's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Jiangsu Recbio Technology Co Business Description

Traded in Other Exchanges
Address
No. 888 Yaocheng Avenue, Medical High-tech District, Jiangsu Province, Taizhou, CHN
Jiangsu Recbio Technology Co Ltd is a vaccine company dedicated to the development and commercialization of safer and more effective vaccines to address the far-unmet public needs. Hygiene needs. The company focuses on the R&D of HPV vaccine candidates. The company's vaccine portfolio currently consists of 12 vaccines, including three strategic products, namely REC603, a recombinant HPV 9-valent vaccine under phase III clinical trial.
Executives
Feng Tao 2201 Interest of corporation controlled by you
Bei Jing Jun Lian Cheng Yuan Gu Quan Tou Zi He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
Zhu Linan 2201 Interest of corporation controlled by you
Jun Lian Zi Ben Guan Li Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you
Bei Jing Jun Qi Jia Rui Qi Ye Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Bei Jing Jun Cheng He Zhong Tou Zi Guan Li He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Tian Jin Jun Lian Jie You Qi Ye Guan Li Zi Xun He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Tian Jin Hui Zhi Yi Hao Qi Ye Guan Li Zi Xun He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Chen Hao 2201 Interest of corporation controlled by you
La Sa Jun Qi Qi Ye Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Shang Hai Chao Rui Yi Yao Ke Ji He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
Lyfe Capital Fund Iii (dragon), L.p.
Liu Yong
Chen Wei 2201 Interest of corporation controlled by you
Zhao Yin Jin Rong Kong Gu Shen Zhen You Xian Gong Si 2201 Interest of corporation controlled by you

Jiangsu Recbio Technology Co Headlines

No Headlines